Twist Bioscience (TWST) Stock: Why The Price Went Up

By Amit Chowdhry ● Feb 2, 2022
  • The stock price of Twist Bioscience Corp (NASDAQ: TWST) increased by 4.93% in the most recent trading session. This is why it happened.

The stock price of Twist Bioscience Corp (NASDAQ: TWST) – a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform – increased by 4.93% in the most recent trading session. Investors are responding positively to Twist Bioscience and Abcam, a global innovator in life sciences reagents and tools, announcing a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development, and commercialization for diagnostic and research applications.

Phage display complements other antibody discovery methods and offers several benefits for tackling challenging targets. And the synthetic nature and the diversity of each Twist library (up to 10 billion variants) enable the rapid identification of antibodies against challenging targets that would otherwise fail due to toxicity or lack of immunogenicity. The recombinant format enables easier genetic engineering and maximizes in vitro manufacturing ensuring batch-to-batch reproducibility and scalability from bench to bedside.

Under the terms of the agreement, Twist Bioscience granted Abcam the right to engage in research and development activities using Twist single domain (VHH) synthetic antibody library. And Abcam has the option to nominate, license, and commercialize antibody sequences for diagnostic and research use, in return for license fees and commercial milestone payments. Twist retains the rights to the same sequences for therapeutic application.


“Twist’s phage library complements our leading recombinant antibody discovery capabilities, adding further scale and diversity and increasing the likelihood of identifying antibodies with the desired properties against emerging or established targets. The partnership supports Abcam and Twist’s commitment to deliver antibodies that have the potential to accelerate the development of innovative research tools, diagnostics, and therapeutics.”

— Alejandra Solache, Ph.D., SVP R&D at Abcam

“This partnership is an important milestone in Twist’s journey as it allows us to access the research and diagnostic market through Abcam’s commitment to advance discovery, development and commercialization of the resulting antibodies. In addition, this agreement lays the foundations for a long term collaboration with Abcam to drive new commercial opportunities. Importantly, because Twist retains the rights to develop the sequences for therapeutic uses, this partnership has the potential to benefit our internal pipeline as well.”

— Emily M. Leproust, Ph.D., CEO and co-founder of Twist

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.